Skip to main navigation
Neoleukin Therapeutics

Investors

Event Details

Canaccord Genuity 42nd Annual Growth Conference

August 10, 2022 at 1:00 PM EDT

View Webcast

Investor Tools

  • Investor FAQs
  • Contact IR
  • Email Alerts

Neoleukin - Investors Menu (Secondary)

  • Press Releases
  • Events & Presentations
  • Financial and Filings
  • Stock Information
  • Analysts
  • Corporate Governance

Neoleukin - Investor Relations

  • About
    • Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Responsibility
    • Contact
  • Science
    • De Novo Protein Design
    • Neoleukin Platform
    • Publications
    • Collaborations & Partnerships
  • Programs
    • NL-201
    • Research
  • News
    • Press Releases
    • Events
    • In The News
    • Media Contact
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial and Filings
    • Stock Information
    • Analysts
    • Corporate Governance
    • Investor FAQs
    • Contact IR
    • Email Alerts
  • Careers
    • Overview
    • Our Values
    • Our Culture
    • Job Opportunities
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Twitter
  • Neoleukin TherapeuticsHome

    • Neoleukin - Investor Relations

  • About
    • Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Responsibility
    • Contact
  • Science
    • De Novo Protein Design
    • Neoleukin Platform
    • Publications
    • Collaborations & Partnerships
  • Programs
    • NL-201
    • Research
  • News
    • Press Releases
    • Events
    • In The News
    • Media Contact
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial and Filings
    • Stock Information
    • Analysts
    • Corporate Governance
    • Investor FAQs
    • Contact IR
    • Email Alerts
  • Careers
    • Overview
    • Our Values
    • Our Culture
    • Job Opportunities
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Twitter
©  Neoleukin Therapeutics, Inc. All rights reserved.
  • Twitter
  • Privacy Policy
  • Terms & Conditions